| Immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy C Karacin, T Eren, E Zeynelgil, GI Imamoglu, M Altinbas, I Karadag, ... Future Oncology 17 (33), 4447-4456, 2021 | 43 | 2021 |
| Comparison of HER2-zero and HER2-low in terms of clinicopathological factors and survival in early-stage breast cancer: A systematic review and meta-analysis Y Ergun, G Ucar, B Akagunduz Cancer Treatment Reviews 115, 102538, 2023 | 41 | 2023 |
| Comparison of gemcitabine monotherapy with gemcitabine and cisplatin combination in metastatic pancreatic cancer: a retrospective analysis Y Ergun, NY Ozdemir, EK Guner, E Esin, MA Sendur, EB Koksoy, ... J BUON 23, 116-121, 2018 | 25 | 2018 |
| Correlation between peripheral blood inflammatory indicators and pathologic complete response to neoadjuvant chemotherapy in locally advanced breast cancer patients T Eren, C Karacin, G Ucar, Y Ergun, O Yazici, Gİ İmamoglu, N Ozdemir Medicine 99 (22), e20346, 2020 | 22 | 2020 |
| The prognostic value of the prognostic nutritional index in patients with metastatic colorectal cancer G Ucar, Y Ergun, Y Acikgoz, D Uncu Asia‐Pacific Journal of Clinical Oncology 16 (5), e179-e184, 2020 | 21 | 2020 |
| Prognostic and predictive value of KRAS mutation number in metastatic colorectal cancer G Ucar, Y Ergun, SA Esen, Y Acikgoz, M Dirikoc, İ Esen, Ö Bal, D Uncu Medicine 99 (39), e22407, 2020 | 21 | 2020 |
| Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy C Karacin, B Oksuzoglu, A Demirci, M Keskinkılıç, NK Baytemür, F Yılmaz, ... BMC cancer 23 (1), 136, 2023 | 20 | 2023 |
| Drug-drug interactions in patients using tyrosine kinase inhibitors: A multicenter retrospective study Y Ergun, NY Ozdemir, S Toptas, A Kurtipek, T Eren, O Yazici, ... J BUON 24 (4), 1719-1726, 2019 | 18 | 2019 |
| Does primary tumor resection contribute to overall survival in unresectable synchronous metastatic colorectal cancer? Y Ergun, O Bal, M Dogan, G Ucar, M Dirikoc, Y Acikgoz, F Bacaksiz, ... Journal of Research in Medical Sciences 25 (1), 14, 2020 | 14 | 2020 |
| Efficacy of regorafenib in the second-and third-line setting for patients with advanced hepatocellular carcinoma: A real life data of multicenter study from Turkey. B Hacioglu, O Kostek, S Karabulut, D Tastekin, C Alandag, B Akagunduz, ... Journal of BU ON.: official journal of the Balkan Union of Oncology 25 (4 …, 2020 | 11 | 2020 |
| Role of hepatosteatosis in HBsAg seroconversion in HBeAg‐negative chronic hepatitis B patients F Bacaksız, H Gökcan, M Akdoğan, DT Gökçe, D Arı, V Gökbulut, Y Ergün, ... International Journal of Clinical Practice 75 (12), e14899, 2021 | 9 | 2021 |
| Anxiety, Insomnia and Pandemic Awareness of Cancer Patients Receiving Chemotherapy During the COVID-19 Pandemic Period. S Akturk Esen, Y Acikgoz, M Yildirim, G Ucar, Y Ergun, M Dirikoc, O Bal, ... UHOD: International Journal of Hematology & Oncology/Uluslararasi Hematoloji …, 2021 | 8 | 2021 |
| The effect of chemotherapy on olfactory function and mucociliary clearance FC Eravcı, G Uçar, KM Özcan, M Çolak, Y Ergün, Y Açıkgöz, ... Supportive Care in Cancer 29, 1635-1641, 2021 | 8 | 2021 |
| KRAS codon 12 and 13 mutations may guide the selection of irinotecan or oxaliplatin in first-line treatment of metastatic colorectal cancer Y Ergun, Y Acikgoz, O Bal, G Ucar, M Dirikoc, E Caliskan Yildirim, ... Expert Review of Molecular Diagnostics 19 (12), 1131-1140, 2019 | 8 | 2019 |
| Gastric cancer patients with bone marrow metastasis: a single-center experience and review of the literature Y Ergun, D Uncu, O Yazici, G Ucar, EK Karabuga, N Zengin Eurasian J Med Oncol 1, 160-3, 2017 | 8 | 2017 |
| Efficacy of adjuvant CDK4/6 inhibitors in hormone receptor-positive breast cancer: a systematic review and meta-analysis Y Ergun, M Dogan, G Ucar, P Karacin, C Karacin Expert Opinion on Pharmacotherapy 24 (17), 1901-1909, 2023 | 7 | 2023 |
| The effect of HER2-low status on pathological complete response and survival in triple-negative breast cancer: a systemic review and meta-analysis Y Ergun, B Akagunduz, C Karacin, S Turker, G Ucar Clinical Breast Cancer 23 (6), 567-575, 2023 | 7 | 2023 |
| Sunitinib or pazopanib: is there any difference between tyrosine kinase inhibitors in the pre-nivolumab setting in metastatic renal cell carcinoma? G Ucar, Y Acikgoz, Y Ergun, O Bal, M Yilmaz, S Karakaya, N Akdeniz, ... Cureus 12 (9), 2020 | 7 | 2020 |
| Combination of trastuzumab and taxane-containing intensified chemotherapy in first-line treatment of HER2-positive advanced gastric cancer M Gürbüz, E Akkuş, A Sakin, S Urvay, AG Demiray, S Şahin, T Şakalar, ... Tumori Journal 107 (5), 416-423, 2021 | 6 | 2021 |
| Saying goodbye to primary endocrine resistance for advanced breast cancer? C Karacin, Y Ergun, OB Oksuzoglu Medical Oncology 38 (1), 5, 2021 | 6 | 2021 |